Recently, it was suggested that the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab could be used in the treatment of rubeosis iridis. Therefore, we aimed to trace the penetration of bevacizumab into the anterior chamber after intravitreal injection of the drug. We found that intravitreally injected bevacizumab penetrates well and quickly into the anterior chamber angle, iris and ciliary body.
Rubeosis iridis, the formation of pathological vessels in the iris, is a severe complication of ischaemic retinal diseases such as proliferative diabetic retinopathy or retinal vascular occlusion. The angiogenic cascade starts with a focal or generalised retinal hypoxia, which may appear in diabetic patients due to occlusive changes in the vessel wall and perfusion disturbances, as well as in all kinds of retinal vascular occlusive disease (branch or central retinal vein or artery occlusion).
A variety of pro-angiogenic growth factors are involved in the process of angiogenesis, although vascular endothelial growth factor A (VEGF-A) seems to be the most potent. For example, VEGF is twice as potent as angiopoietin-2 in interrupting tight junctions in retinal endothelial cell monolayers.
1 Retinal hypoxia upregulates VEGF-A expression, leading to the formation of leaky retinal neovascularisation. The high concentrations of VEGF-A also reach the vitreous and the anterior chamber, and in this way act on the tissues of the anterior segment, leading to the formation of neovascularisation in the chamber angle and the iris. These neovascularisations can reduce visual acuity due to haemorrhages, and they also impair the drainage of aqueous humour in the chamber angle, leading to secondary neovascular glaucoma, which is a severe complication of retinal ischaemic disease. This leads to damage of the optic nerve. We also wanted to trace the penetration of bevacizumab in the anterior segment -bearing in mind the question of the penetration of bevacizumab through the retina -even though structures that are not as tight as the retina had to be overcome. 11 Therefore, we injected 1.25mg bevacizumab (Avastin ® , Roche) into the vitreous cavity of primate eyes under general anaesthesia. Control eyes were not treated. The eyes were enucleated on days one, four and 14 and prepared for immunohistochemistry with an antibody to localise bevacizumab.
We found that intravitreally injected bevacizumab penetrates well and quickly into the anterior chamber angle (see Figure 1) , the iris Figure 2 ) and the ciliary body (see Figure 3) . In all of these tissues of the anterior segment, bevacizumab is preferably located in the vessel walls, which are the sites of secretion and binding of VEGF to its receptors on the vascular endothelial cells. 12 The same distribution is true for the choriocapillaris (see Figure 4) . The highest concentration of bevacizumab is present on days one to four after injection, the penetration into the iris appearing to be faster (day one) than that into the anterior chamber angle and ciliary body (day four).
These findings are consistent with the clinically described regression of iris neovascularisation one to three days after injection, and are also consistent with the observation that the intracameral peak concentration of bevacizumab appears on day three after intravitreal injection.
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The intravitreal peak concentration and the anti-oedematous effect on the choriocapillaris were found to be present on day four, 7 obviously paralleling the situation in the anterior chamber. Bevacizumab immunoreactivity in the iris on day one (see Figure 2 ) is more intense and abundant than in the anterior chamber angle or in the ciliary body, but it then appears to be eliminated more quickly than from the ciliary body. The latter shows an intense positivity for bevacizumab even on day 14 (see Figure 3 ).
In the chamber angle, there was a time-related distribution of bevacizumab: on day one after injection more intense staining was present on the side of Schlemm's canal facing the anterior chamber (see Figure 1) , while on day four the staining was more intense on the exterior side facing the sclera. This finding may reflect a progressive penetration through the tissue from the anterior chamber towards the sclera, paralleling the progressive penetration of bevacizumab through the retinal layers during the first week, as described by Heiduschka et al.
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Certain blood vessels showed strong immunoreactivity for bevacizumab in their lumen (see Figures 2 and 3) . 
